SARAH ZIELINSKI: Open Payments
NPI 1912574120 · OKEMOS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,134 in 49 payments from 19 companies in 2025. Trend: 2023 $743 · 2024 $1,475 · 2025 $1,134
Food & beverage: $1,135
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $264 |
| Lilly USA, LLC | 5 | $161 |
| Octapharma USA, Inc. | 1 | $125 |
| Novo Nordisk Inc | 5 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $78 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $51 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| PFIZER INC. | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
Products named: QULIPTA, FIBRYGA, ZEPBOUND, VRAYLAR, CAPLYTA, REXULTI, Ozempic, Kerendia.
Industry payments across MI — which companies pay providers there.
